Scholar Rock Holding Co. (NASDAQ:SRRK) Insider Jing L. Marantz Sells 5,655 Shares

Scholar Rock Holding Co. (NASDAQ:SRRK) insider Jing L. Marantz sold 5,655 shares of the firm’s stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $44.20, for a total transaction of $249,951.00. Following the completion of the transaction, the insider now directly owns 67,200 shares in the company, valued at approximately $2,970,240. The trade was a 7.76 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Scholar Rock Stock Up 4.1 %

Shares of Scholar Rock stock traded up $1.75 on Tuesday, hitting $44.88. The company had a trading volume of 1,004,933 shares, compared to its average volume of 1,009,194. Scholar Rock Holding Co. has a twelve month low of $6.76 and a twelve month high of $46.19. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.88 and a quick ratio of 3.88. The stock has a 50-day moving average of $39.58 and a 200-day moving average of $23.33. The firm has a market capitalization of $4.20 billion, a P/E ratio of -19.10 and a beta of 0.52.

Hedge Funds Weigh In On Scholar Rock

A number of large investors have recently added to or reduced their stakes in SRRK. GAMMA Investing LLC boosted its position in shares of Scholar Rock by 51.8% during the fourth quarter. GAMMA Investing LLC now owns 788 shares of the company’s stock worth $34,000 after buying an additional 269 shares during the period. JPMorgan Chase & Co. boosted its position in Scholar Rock by 1.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 38,726 shares of the company’s stock worth $310,000 after acquiring an additional 379 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Scholar Rock by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,895 shares of the company’s stock worth $25,000 after acquiring an additional 514 shares in the last quarter. Nisa Investment Advisors LLC raised its holdings in shares of Scholar Rock by 1,321.8% in the fourth quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company’s stock valued at $48,000 after purchasing an additional 1,031 shares during the last quarter. Finally, Cinctive Capital Management LP grew its position in Scholar Rock by 7.2% in the third quarter. Cinctive Capital Management LP now owns 42,902 shares of the company’s stock valued at $344,000 after purchasing an additional 2,869 shares in the last quarter. Institutional investors own 91.08% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. JPMorgan Chase & Co. raised their price target on Scholar Rock from $18.00 to $31.00 and gave the stock an “overweight” rating in a research report on Monday, October 14th. BMO Capital Markets raised their target price on Scholar Rock from $34.00 to $38.00 and gave the stock an “outperform” rating in a report on Friday, October 11th. Piper Sandler increased their price target on shares of Scholar Rock from $28.00 to $42.00 and gave the company an “overweight” rating in a research report on Tuesday, October 15th. Wedbush restated an “outperform” rating and set a $47.00 price objective on shares of Scholar Rock in a report on Thursday, January 9th. Finally, HC Wainwright increased their target price on shares of Scholar Rock from $40.00 to $50.00 and gave the stock a “buy” rating in a report on Tuesday, November 26th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Scholar Rock has a consensus rating of “Buy” and a consensus price target of $40.43.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.